Editing Clinical Trials (section)

== What CAR-T Cell Therapies Are Available for Mesothelioma? ==

CAR-T (Chimeric Antigen Receptor T-cell) therapy represents one of the most promising frontiers in mesothelioma treatment, with multiple trials demonstrating unprecedented survival outcomes.<ref>[https://www.mesotheliomalawyercenter.org/financial-compensation-form/ Financial Compensation Form], Mesothelioma Lawyer Center</ref>

=== TNhYP218 Trial at National Cancer Institute (NCT06885697) ===

This Phase I dose-escalation study evaluates anti-mesothelin TNaive/SCM hYP218 CAR T cells, designed for enhanced tumor infiltration and persistence.

'''Trial Details:'''
* '''Status:''' Recruiting since 2025
* '''Location:''' National Cancer Institute, Bethesda, Maryland
* '''Innovation:''' Targets membrane-proximal epitope of mesothelin, showing 2-4 fold better tumor killing than membrane-distal approaches in preclinical studies
* '''Eligibility:''' Age 18 or older, mesothelin expression greater than 50% of tumor cells, ECOG 0-1
* '''Monitoring:''' Patients must remain within 2 hours of NIH for 30 days post-infusion
* '''Follow-up:''' 15 years per FDA requirement

=== Memorial Sloan Kettering Intrapleural CAR-T Program (NCT04577326) ===

This groundbreaking program pioneered regional delivery of CAR-T cells directly into the pleural space, minimizing systemic toxicity while maximizing tumor contact.<ref>[https://dandell.com/mesothelioma-lawyer/new-york/ New York Mesothelioma Lawyers], Danziger & De Llano</ref>

{| style="width:100%; background:#d4edda; border:1px solid #28a745; border-left:5px solid #28a745; border-radius:4px; margin:1em 0;"
|-
| style="padding:15px; color:#155724;" | '''✓ Breakthrough Results:''' Memorial Sloan Kettering's intrapleural CAR-T program achieved '''83% one-year survival''' for malignant pleural mesothelioma patients—dramatically exceeding historical outcomes of 12-16 months median survival with standard therapy.
|}

'''Published Results:'''
* '''One-year survival:''' 83% for malignant pleural mesothelioma patients
* '''CAR-T persistence:''' Cells detected in peripheral blood for more than 100 days in 39% of patients
* '''Durable responses:''' One patient achieved partial response lasting 26 months
* '''Safety profile:''' Intrapleural administration was safe and well tolerated
* '''Combination approach:''' 18 patients received CAR-T with pembrolizumab, demonstrating enhanced function

=== SynKIR-110 Trial (STAR-101, NCT05568680) ===

This novel approach uses KIR-CAR T cells targeting mesothelin across multiple tumor types including mesothelioma.<ref>[https://mesothelioma.net/immunotherapy/ Immunotherapy for Mesothelioma], Mesothelioma.net</ref>

* '''Status:''' Completed enrollment of Cohorts 1-3 without dose-limiting toxicities as of May 2025
* '''Sites:''' Multiple US locations including Penn Medicine
* '''Safety:''' No dose-limiting toxicities in completed cohorts